Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S4-E19.6 - From the Vault: REGENERATE Redux: Clearing The Finish Line?
Description: On July 7 2022, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH fibrosis. In this conversation From the Vault, Stephen Harrison leads Jörn Schattenberg, Louise Campbell and Roger Green in considering whether the evidence in the new release will be sufficient to get the drug approved.Stephen starts by noting that we have not heard anything about the results of the REVERSE trial, which evaluated obeticholic acid (OCA) in patients with compensated cirrhosis. As he notes, even if OCA i...